Funded Programs Help Support Linkage To HIV/AIDS Care In Underserved Communities
Titusville, NJ, (January 5th, 2012) - Janssen Therapeutics,
Division of Janssen Products, LP, today announced the
funding recipients of the Linking In-Need Communities to
Care Initiative™ (LINCC). The LINCC Initiative provides
charitable contributions to select community-based programs
that address barriers to accessing and remaining in
HIV/AIDS care in disadvantaged communities. For more
information about the LINCC Initiative, please visit .
Recipients received charitable contributions of up to
$40,000 in support of programs designed to address
personal, societal and structural barriers to care for
individuals diagnosed with HIV/AIDS. Funded programs
addressed well-documented barriers such as stigma and
isolation, mental health issues and substance use, lack of
health information and resources, lack of personal support
structures and medical system inefficiencies.
The following 14 organizations received funding through the
LINCC Initiative:
- Afiya Center (Dallas, TX)
- AID Upstate (Greenville, SC)
- AIDS Alabama (Birmingham, AL)
- AIDS Foundation of Chicago (Chicago, IL)
- Center for Health Justice (Los Angeles, CA)
- Children's Diagnostic & Treatment Center, Inc. (Ft. Lauderdale, FL)
- Christie's Place (San Diego, CA)
- Community Education Group (Washington, DC)
- Family Planning Council/SafeGuards (Philadelphia, PA)
- Foundation of UMDNJ (Newark, NJ)
- Howard Brown Health Center (Chicago, IL)
- Montgomery AIDS Outreach (Montgomery, AL)
- Nashville Cares (Nashville, TN)
- Women's HIV Program at UCSF (San Francisco, CA)
"Janssen Therapeutics is honored to support these
outstanding HIV organizations for their efforts in
strengthening access to care and making a difference in
their communities," said Vanessa Broadhurst, President,
Janssen Therapeutics. "We are committed to addressing
common barriers that can prevent people living with HIV
from accessing and remaining in care, and we believe these
programs can help patients and their loved ones."
The LINCC Initiative extends the Janssen Therapeutics
tradition of funding endeavors that address areas of
significant unmet need in the HIV/AIDS community, while at
the same time providing private sector funding to
community-based organizations that are working to fulfill
the goals of the National HIV/AIDS Strategy. Programs
funded through the LINCC Initiative focus on improving
access to care, optimizing health outcomes and reducing
HIV-related health disparities, particularly in underserved
communities.
This LINCC Initiative is the fourth annual funding project
for Janssen Therapeutics. In total, these four
initiatives have contributed nearly $2 million to
community-based HIV/AIDS service organizations in the U.S.
since 2008.
U.S.-based 501(c)3, tax-exempt organizations focusing on
HIV/AIDS were eligible to submit proposals to the LINCC
Initiative. Submissions were assessed on their potential to
address access to HIV to care and treatment, and to link
diagnosed patients to medical and supportive care.
About HIV in the U.S.
Early access to HIV care and treatment has been shown to
prolong life, improve health outcomes and reduce the
likelihood of viral transmission. According to the Centers
for Disease Control and Prevention, nearly one-third of
people diagnosed with HIV in the U.S. are not currently
receiving care and/or treatment. Barriers to accessing and
staying in care are significant and can be cultural,
psychological, emotional, structural or societal in
nature.
About Janssen Therapeutics
At Janssen, we are dedicated to addressing and solving some
of the most important unmet medical needs of our time in
HIV and other infectious diseases. Driven by our
commitment to patients, we develop innovative products,
services and healthcare solutions to help people throughout
the world. Headquartered in Titusville, New Jersey,
Janssen Therapeutics, Division of Janssen Products, LP, is
one of the Janssen Pharmaceutical Companies. Visit
for more information.
# # #
Media Contact: Tricia Geoghegan
Office: 609-730-3746
Mobile: 609-462-8764
distribué par | Ce noodl a été diffusé par Johnson & Johnson et initialement mise en ligne sur le site http://www.jnj.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-05 17:58:34 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |